Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial

The efficacy and safety of insulin degludec (IDeg) was compared with insulin detemir (IDet), both administered once daily (OD) as basal treatment in participants with type 1 diabetes mellitus (T1DM). The primary outcome was non‐inferiority of IDeg to IDet in glycated haemoglobin (HbA1c) reduction after 26 weeks.

• Publication year

  2014

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2014-05-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.12298PMID 24702700PMCID 4237553
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

  2013cited by this paper
• American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

  2013influential reference
• Insulin degludec in Type 1 diabetes

  2013cited by this paper
• Standards of Medical Care in Diabetes—2013

  2012cited by this paper
• Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

  2012influential reference
• Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

  2012cited by this paper
• Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

  2012cited by this paper
• Potential Health Risks From Beverages Containing Fructose Found in Sugar or High-Fructose Corn Syrup

  2012cited by this paper
• Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile compared with insulin glargine

  2012cited by this paper
• Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

  2012cited by this paper
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

  2012cited by this paper
• Update in the CNS response to hypoglycemia.

  2012cited by this paper
• The Gains from Delegation Revisited: Price-Level Targeting, Speed-Limit and Interest Rate Smoothing Policies

  2011cited by this paper
• Hypoglycemia Rates with Basal Insulin Analogs

  2011cited by this paper
• The impact of non-severe hypoglycemic events on work productivity and diabetes management.

  2011cited by this paper
• Insulin Degludec in Type 1 Diabetes

  2011cited by this paper
• Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 Diabetes: Evidence from a Clinical Audit

  2010cited by this paper
• Long‐acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta‐analysis

  2009cited by this paper
• Switching patients from insulin glargine‐based basal‐bolus regimens to a once daily insulin detemir‐based basal‐bolus regimen: results from a subgroup of the PREDICTIVE™ study *

  2009cited by this paper
• Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects

  2009cited by this paper
• Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 Diabetes

  2009cited by this paper
• Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.

  2009cited by this paper
• How hypoglycaemia can affect the life of a person with diabetes

  2008cited by this paper
• Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes

  2007cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Treatment DOI: 10.1111/j.1464-5491.2008.02407.x

  2007cited by this paper
• Standards of medical care in diabetes.

  2005cited by this paper
• Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes

  2005cited by this paper
• Insulin detemir used in basal‐bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

  2005cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

  2004cited by this paper
• Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

  2004cited by this paper
• Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.

  2004influential reference
• Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes.

  2002cited by this paper
• WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: Ethical Principles for Medical Research Involving Human Subjects

  2001cited by this paper
• ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.

  2001cited by this paper
• The Diabetes Control and Complications Trial

  1998cited by this paper
• Hypoglycemia: Incidence and Clinical Predictors in a Large Population-Based Sample of Children and Adolescents with IDDM

  1997cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Abnormal Glucose Counterregulation in Insulin-dependent Diabetes Mellitus: Interaction of Anti-Insulin Antibodies and Impaired Glucagon and Epinephrine Secretion

  1983cited by this paper

• Trends in baseline HbA1c and body-mass index in randomised trials of people with type 1 diabetes from 1993 to 2025: an IMI2 SOPHIA systematic review and meta-analysis

  2025cites this paper
• Continuous Glucose Monitoring-Derived Glucometrics in Adults with Type 1 Diabetes When Switching Basal Insulins

  2024cites this paper
• Pharmacological characteristics of once‐weekly insulin icodec in Japanese individuals with type 1 diabetes

  2024cites this paper
• Which Diabetes Patients Will Benefit the Most from Once-Weekly Basal Insulin Analogs? A Review with a Special Focus on Type 1 Diabetes Patients

  2024cites this paper
• Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target trials: A narrative review

  2024cites this paper
• Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.

  2023cites this paper
• Weekly insulin: a paradigm shift in type 1 diabetes therapy.

  2023cites this paper
• Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes

  2023cites this paper
• Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.

  2022cites this paper
• Insulin Titration Guidelines for Patients With Type 1 Diabetes: It Is About Time!

  2022cites this paper
• Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons

  2022cites this paper
• Pregnancy outcomes in women with type 1 diabetes using insulin degludec

  2022cites this paper
• Randomized controlled study to evaluate the impact of flexible patient‐controlled visits in people with type 1 diabetes: The DiabetesFlex Trial

  2022cites this paper
• Pregnancy outcomes in women with type 1 diabetes using insulin degludec: response to Kamran et al

  2022cites this paper
• Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan

  2021cites this paper
• Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review

  2020cites this paper
• Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review

  2020cites this paper
• A importância do profissional farmacêutico na qualidade de vida dos pacientes diabéticos idosos

  2020cites this paper
• Insulintherapie – neue Insulinanaloga

  2019cites this paper
• (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.

  2019cites this paper
• Modelling the glucose-insulin system of type 2 diabetes patients using ARMAX models

  2019cites this paper
• Comparative effectiveness and harms of long‐acting insulins for type 1 and type 2 diabetes: A systematic review and meta‐analysis

  2019cites this paper
• Therapeutic Class Overview Insulin and Combination Agents

  2019influential citation
• Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus

  2019cites this paper
• Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety

  2019cites this paper
• Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: An observational study of 22 cases.

  2019cites this paper
• Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study

  2018cites this paper
• Unmet needs in children with diabetes: the role of basal insulin.

  2017cites this paper
• Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine

  2017cites this paper
• Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study

  2017cites this paper
• Satisfacción con el tratamiento y calidad de vida en pacientes con diabetes mellitus tipo 1 e hipoglucemias tratados con insulina Degludec

  2017cites this paper
• Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls

  2017cites this paper
• Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus.

  2016cites this paper
• Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1‐year treat‐to‐target trial

  2016cites this paper
• Similar HbA1c reduction and hypoglycaemia with variable‐ vs fixed‐time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study

  2016cites this paper
• An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Degludec U-100 and U-200.

  2016cites this paper
• Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST ® T1)

  2016cites this paper
• An Evolutionary Perspective on Basal Insulin in Diabetes Treatment LEARNING

  2016cites this paper
• Existing Insulin Therapies

  2016cites this paper
• A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects

  2016cites this paper
• S 2 Introduction S 3 Role of Insulin Therapy in Diabetes

  2016cites this paper
• A primer on concentrated insulins: what an internist should know

  2016cites this paper
• Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin

  2016cites this paper
• Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide

  2016cites this paper
• Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources

  2015cites this paper
• Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus

  2015cites this paper
• Insulin in ramadan.

  2015cites this paper
• Management of Severe Insulin Resistance in Patients with Type 1 Diabetes

  2015cites this paper
• Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

  2015cites this paper
• Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan

  2015cites this paper
• Recent Advances in Insulin Therapy for Diabetes

  2014cites this paper